Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,471,941
  • Shares Outstanding, K 72,048
  • Annual Sales, $ 356,070 K
  • Annual Income, $ 89,830 K
  • 60-Month Beta 1.57
  • Price/Sales 3.34
  • Price/Cash Flow 14.73
  • Price/Book 5.12
Trade CHRS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.25
  • Number of Estimates 4
  • High Estimate 0.40
  • Low Estimate 0.16
  • Prior Year 0.53
  • Growth Rate Est. (year over year) -52.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.68 +31.24%
on 12/29/20
22.20 -1.40%
on 01/27/21
+4.54 (+26.17%)
since 12/24/20
3-Month
16.44 +33.15%
on 11/02/20
22.20 -1.40%
on 01/27/21
+4.06 (+22.77%)
since 10/27/20
52-Week
10.86 +101.54%
on 03/18/20
23.03 -4.95%
on 02/20/20
+3.16 (+16.87%)
since 01/27/20

Most Recent Stories

More News
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation committee of the Company's board of directors granted options to...

CHRS : 21.79 (+6.66%)
US Biosimilars Market to Rise at a Staggering 46.2% CAGR and Hit USD 22,996 Million till 2027; Breakthrough Concepts in Treatment of Severe Diseases will Bode Well for Market Growth, says Fortune Business Insights(TM)

The US Biosimilars Market size is projected to reach USD 22,966 million by the end of 2027. The presence of several large scale companies that are engaged in the research and development of efficient biosimilars...

ABBV : 103.13 (-5.21%)
AMGN : 252.45 (-2.38%)
CHRS : 21.79 (+6.66%)
LLY : 206.30 (-3.02%)
PFE : 36.34 (-2.60%)
TEVA : 12.14 (-1.46%)
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors

Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021.

CHRS : 21.79 (+6.66%)
Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference

Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that senior management will present at the virtual 39 Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50...

CHRS : 21.79 (+6.66%)
JPM : 128.10 (-2.64%)
First Week of August 2021 Options Trading For Coherus BioSciences (CHRS)

Investors in Coherus BioSciences Inc saw new options become available this week, for the August 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

CHRS : 21.79 (+6.66%)
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee of the Company's board of directors granted options to...

CHRS : 21.79 (+6.66%)
Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Biosimilar Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995085/?utm_source=GNW...

AGN : 193.02 (+0.02%)
CHRS : 21.79 (+6.66%)
First Week of CHRS January 2021 Options Trading

Investors in Coherus BioSciences Inc saw new options become available this week, for the January 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CHRS options...

CHRS : 21.79 (+6.66%)
Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. ("Coherus" or the "Company", Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation committee of the Company's board of directors granted options to...

CHRS : 21.79 (+6.66%)
Coherus BioSciences (CHRS) Lags Q3 Earnings and Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?...

CHRS : 21.79 (+6.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 22.33
2nd Resistance Point 21.49
1st Resistance Point 20.96
Last Price 21.79
1st Support Level 19.59
2nd Support Level 18.75
3rd Support Level 18.22

See More

52-Week High 23.03
Last Price 21.79
Fibonacci 61.8% 18.38
Fibonacci 50% 16.95
Fibonacci 38.2% 15.51
52-Week Low 10.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar